Alembic Pharmaceuticals’ wholly owned subsidiary -- Alembic Pharmaceuticals Inc is all set to acquire Utility Therapeutics (Utility). The objective behind the acquisition is to market the USFDA approved product and underdevelopment product owned by the Utility in USA. The transaction is expected to complete within 30 days. The cost of acquisition is around $12 million in staggered manner over period of time, depending on milestones achieved.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
